Prognostic usefulness of sentinel lymph node biopsy for patients who have clinically node negative, localized, primary invasive cutaneous melanoma: A bayesian analysis using informative published reports

Archives of Dermatology

Volumn 147, Issue 4, 2011, Pages 408-415

  Rhodes, Arthur R ^a  

^a RUSH MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER INVASION; CANCER MORTALITY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DATA BASE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MELANOMA; METASTASIS POTENTIAL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; SYSTEMATIC REVIEW; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BAYES THEOREM; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; YOUNG ADULT;

EID: 79953903981     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2010.371     Document Type: Article

References (76)

1. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127(4):392-399.
2. Morton DL, Cochran AJ. The case for lymphatic mapping and sentinel lymphadenectomy in the management of primary melanoma. Br J Dermatol. 2004;151(2):308-319. (Pubitemid 39215144)
3. Morton DL, Thompson JF, Cochran AJ, et al; MSLT Group. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355(13):1307-1317. (Pubitemid 44465459)
4. Koskivuo I, Talve L, Vihinen P, Mäki M, Vahlberg T, Suominen E. Sentinel lymph node biopsy in cutaneous melanoma: a case-control study. Ann Surg Oncol. 2007;14(12):3566-3574. (Pubitemid 350160141)
5. Leiter U, Buettner PG, Bohnenberger K, et al. Sentinel lymph node dissection in primary melanoma reduces subsequent regional lymph node metastasis as well as distant metastasis after nodal involvement. Ann Surg Oncol. 2010;17(1):129-137.
6. Gutzmer R, Al Ghazal M, Geerlings H, Kapp A. Sentinel node biopsy in melanoma delays recurrence butdoesnotchangemelanoma-related survival: a retrospective analysis of 673 patients. Br J Dermatol. 2005;153(6):1137-1141. (Pubitemid 41779567)
7. Kingham TP, Panageas KS, Ariyan CE, Busam KJ, Brady MS, Coit DG. Outcome of patients with a positive sentinel lymph node who do not undergo completion lymphadenectomy. Ann Surg Oncol. 2010;17(2):514-520.
8. Wong SL, Morton DL, Thompson JF, et al. Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multiinstitutional study. Ann Surg Oncol. 2006;13(6):809-816. (Pubitemid 43727365)
9. Boutron I, Dutton S, Ravaud P, Altman DG. Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA. 2010;303(20):2058-2064.
10. Balch CM, Gershenwald JE, Soong S-J, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199-6206.
11. Balch CM, Cascinelli N. Sentinel-node biopsy in melanoma. N Engl J Med. 2006;355(13):1370-1371. (Pubitemid 44465466)
12. Sondak VK, Zager JS, Messina JL, Thomas JM. Sentinel lymph node biopsy as the standard of care for cutaneous melanoma. Clin Adv Hematol Oncol. 2007;5(6):483-490.
13. Sondak VK, Messina JL. Lymphangiogenesis: host and tumor factors in nodal metastasis. Arch Dermatol. 2008;144(4):536-537. (Pubitemid 351581113)
14. Kanzler MH. The current status of evaluation and treatment of high-risk cutaneous melanoma: therapeutic breakthroughs remain elusive. Arch Dermatol. 2007;143(6):785-787. (Pubitemid 46955740)
15. Vecchio TJ. Predictive value of a single diagnostic test in unselected populations. N Engl J Med. 1966;274(21):1171-1173.
16. Gomez-Rivera F, Santillan A, McMurphey AB, et al. Sentinel node biopsy in patients with cutaneous melanoma of the head and neck: recurrence and survival study. Head Neck. 2008;30(10):1284-1294.
17. Cecchi R, Buralli L, Innocenti S, De Gaudio C. Sentinel lymph node biopsy in patients with thin melanomas. J Dermatol. 2007;34(8):512-515. (Pubitemid 47228525)
18. Jacobs IA, Chang CK, DasGupta TK, Salti GI. Role of sentinel lymph node biopsy in patients with thin (<1 mm) primary melanoma. Ann Surg Oncol. 2003;10(5):558-561. (Pubitemid 40486920)
19. Starz H, Balda B-R. Benefit of sentinel lymphadenectomy for patients with non-ulcerated cutaneous melanomas in the Breslow range between 0.76 and 1 mm: a follow-up study of 148 patients. Int J Cancer. 2007;121(3):689-693. (Pubitemid 46986505)
20. Ranieri JM, Wagner JD, Wenck S, Johnson CS, Coleman JJ III. The prognostic importance of sentinel lymph node biopsy in thin melanoma. Ann Surg Oncol. 2006;13(7):927-932.
21. Essner R, Chung MH, Bleicher R, Hsueh E, Wanek L, Morton DL. Prognostic implications of thick (≥4-mm) melanoma in the era of intraoperative lymphatic mapping and sentinel lymphadenectomy. Ann Surg Oncol. 2002;9(8):754-761.
22. Moehrle M, Schippert W, Rassner G, Garbe C, Breuninger H. Micrometastasis of a sentinel lymph node in cutaneous melanoma is a significant prognostic factor for disease-free survival, distant-metastasis-free survival, and overall survival. Dermatol Surg. 2004;30(10):1319-1328. (Pubitemid 39422960)
23. Topar G, Eisendle K, Zelger B, Fritsch P. Sentinel lymph node status in melanoma: a valuable prognostic factor? Br J Dermatol. 2006;154(6):1080-1087. (Pubitemid 43727388)
24. Kettlewell S, Moyes C, Bray C, et al. Value of sentinel node status as a prognostic factor in melanoma: prospective observational study. BMJ. 2006;332(7555):1423-1425. (Pubitemid 44365321)
25. Vuylsteke RJCLM, van Leeuwen PAM, Statius Muller MG, Gietema HA, Kragt DR, Meijer S. Clinical outcome of stage I/II melanoma patients after selective sentinel lymph node dissection: long-term follow-up results. J Clin Oncol. 2003;21(6):1057-1065. (Pubitemid 46594135)
26. Rex J, Paradelo C, Mangas C, et al. Single-institution experience in the management of patients with clinical stage I and II cutaneous melanoma: results of sentinel lymph node biopsy in 240 cases. Dermatol Surg. 2005;31(11, pt 1):1385-1393.
27. Mangas C, Hilari JM, Paradelo C, et al. Prognostic significance of molecular staging study of sentinel lymph nodes by reverse transcriptase- polymerase chain reaction for tyrosinase in melanoma patients. Ann Surg Oncol. 2006;13(7):910-918.
28. Lock-Andersen J, Horn J, Sjøstrand H, Nürnberg BM, Stokholm KH. Sentinel node biopsy in cutaneous melanoma. Scand J Plast Reconstr Surg Hand Surg. 2006;40(1):24-31. (Pubitemid 43155554)
29. Romanini A, Manca G, Pellegrino D, et al. Molecular staging of the sentinel lymph node in melanoma patients: correlation with clinical outcome. Ann Oncol. 2005;16(11):1832-1840. (Pubitemid 41631249)
30. Roka F, Kittler H, Cauzig P, et al. Sentinel node status in melanoma patients is not predictive for overall survival upon multivariate analysis. Br J Cancer. 2005;92(4):662-667. (Pubitemid 40460601)
31. Oliveira AF, Santos ID, Tucunduva TC, et al. Sentinel lymph node biopsy in cutaneous melanoma. Acta Cir Bras. 2007;22(5):332-336. (Pubitemid 47616098)
32. Tatlidil C, Parkhill WS, Giacomantonio CA, Greer WL, Morris SF, Walsh NM. Detection of tyrosinase mRNA in the sentinel lymph nodes of melanoma patients is not a predictor of short-term disease recurrence. Mod Pathol. 2007;20(4):427-434. (Pubitemid 46482366)
33. Jansen L, Nieweg OE, Peterse JL, Hoefnagel CA, Olmos RA, Kroon BB. Reliability of sentinel lymph node biopsy for staging melanoma. Br J Surg. 2000;87(4):484-489. (Pubitemid 30192962)
34. Wells KE, Rapaport DP, Cruse CW, et al. Sentinel lymph node biopsy in melanoma of the head and neck. Plast Reconstr Surg. 1997;100(3):591-594. (Pubitemid 27381061)
35. Blaheta H-J, Ellwanger U, Schittek B, et al. Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. J Invest Dermatol. 2000;114(4):637-642. (Pubitemid 30226993)
36. Shivers S, Jakub J, Pendas S, Reintgen D. Molecular staging for patients with malignant melanoma. Expert Rev Anticancer Ther. 2007;7(11):1665-1674. (Pubitemid 350303020)
37. Manca G, Romanini A, Pellegrino D, et al. Optimal detection of sentinel lymph node metastases by intraoperative radioactive threshold and molecular analysis in patients with melanoma. J Nucl Med. 2008;49(11):1769-1775.
38. Gad D, Høilund-Carlsen PF, Bartram P, Clemmensen O, Bischoff-Mikkelsen M. Staging patients with cutaneous malignant melanoma by same-day lymphoscintigraphy and sentinel lymph node biopsy: a single-institutional experience with emphasis on recurrence. J Surg Oncol. 2006;94(2):94-100. (Pubitemid 44267189)
39. Howman-Giles R, Shaw HM, Scolyer RA, et al. Sentinel lymph node biopsy in pediatric and adolescent cutaneous melanoma patients. Ann Surg Oncol. 2010;17(1):138-143.
40. Sox HC Jr. Probability theory in the use of diagnostic tests: an introduction to critical study of the literature. Ann Intern Med. 1986;104(1):60-66.
41. Cascinelli N, Bombardieri E, Bufalino R, et al. Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. J Clin Oncol. 2006;24(27):4464-4471. (Pubitemid 46630985)
42. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17(3):976-983. (Pubitemid 29109331)
43. Berk DR, Johnson DL, Uzieblo A, Kiernan M, Swetter SM. Sentinel lymph node biopsy for cutaneous melanoma: the Stanford experience, 1997-2004. Arch Dermatol. 2005;141(8):1016-1022.
44. Nowecki ZI, Rutkowski P, Nasierowska-Guttmejer A, Ruka W. Sentinel lymph node biopsy in melanoma patients with clinically negative regional lymph nodes - one institution's experience. Melanoma Res. 2003;13(1):35-43. (Pubitemid 36269812)
45. Warycha MA, Zakrzewski J, Ni Q, et al. Meta-analysis of sentinel lymph node positivity in thin melanoma (≤1 mm). Cancer. 2009;115(4):869-879.
46. Morris KT, Busam KJ, Bero S, Patel A, Brady MS. Primary cutaneous melanoma with regression does not require a lower threshold for sentinel lymph node biopsy. Ann Surg Oncol. 2008;15(1):316-322.
47. Testori A, De Salvo GL, Montesco MC, et al; Italian Melanoma Intergroup. Clinical considerations on sentinel node biopsy in melanoma from an Italian multicentric study on 1,313 patients (SOLISM-IMI). Ann Surg Oncol. 2009;16(7):2018-2027.
48. Gershenwald JE, Mansfield PF, Lee JE, Ross MI. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (≥4 mm) primary melanoma. Ann Surg Oncol. 2000;7(2):160-165. (Pubitemid 30164687)
49. Vermeeren L, van der Ent FWC, Sastrowijoto PSH, Hulsewé KWE. Thick melanoma: prognostic value of positive sentinel nodes. World J Surg. 2009;33(11):2464-2468.
50. Gajdos C, Griffith KA, Wong SL, et al. Is there a benefit to sentinel lymph node biopsy in patients with T4 melanoma? Cancer. 2009;115(24):5752-5760.
51. Ferrone CR, Panageas KS, Busam K, Brady MS, Coit DG. Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status. Ann Surg Oncol. 2002;9(7):637-645. (Pubitemid 34857980)
52. Carlson GW, Murray DR, Hestley A, Staley CA, Lyles RH, Cohen C. Sentinel lymph node mapping for thick (≥4-mm) melanoma: should we be doing it? Ann Surg Oncol. 2003;10(4):408-415.
53. Gutzmer R, Satzger I, Thoms K-M, et al. Sentinel lymph node status is the most important prognostic factor for thick (≥4 mm) melanomas. J Dtsch Dermatol Ges. 2008;6(3):198-203. (Pubitemid 351361065)
54. Thompson JF, Shaw HM. The prognosis of patients with thick primary melanomas: is regional lymph node status relevant, and does removing positive regional nodes influence outcome? Ann Surg Oncol. 2002;9(8):719-722.
55. Rossi CR, Pasquali S, Mocellin S. Actual false-negative rate prompts the routine use of ultrasound scan before and after sentinel node biopsy in melanoma. Ann Surg Oncol. 2008;15(10):2976-2977. doi:10.1245/s10434-008-9999-6.
56. Sondak VK, Zager JS. Who is to blame for false-negative sentinel node biopsies in melanoma? Ann Surg Oncol. 2010;17(3):670-673.
57. Stitzenberg KB, Thomas NE, Beskow LM, Ollila DW. Population-based analysis of lymphatic mapping and sentinel lymphadenectomy utilization for intermediate thickness melanoma. J Surg Oncol. 2006;93(2):100-108.
58. Grange F, Vitry F, Granel-Brocard F, et al. Variations in management of stage I to stage III cutaneous melanoma: a population-based study of clinical practices in France. Arch Dermatol. 2008;144(5):629-636. (Pubitemid 351724423)
59. Cormier JN, Xing Y, Ding M, et al. Population-based assessment of surgical treatment trends for patients with melanoma in the era of sentinel lymph node biopsy. J Clin Oncol. 2005;23(25):6054-6062.
60. Garreau JR, Nelson J, Cook D, et al. Geographic variation in sentinel node adaptation by practicing surgeons in Oregon. Am J Surg. 2005;189(5):616-620. (Pubitemid 40602955)
61. Lens MB, Dawes M, Newton-Bishop JA, Goodacre T. Management of regional lymph nodes in patients with malignant melanoma: questionnaire survey of UK current practice. Br J Plast Surg. 2002;55(5):372-375. (Pubitemid 34993880)
62. Bilimoria KY, Balch CM, Bentrem DJ, et al. Complete lymph node dissection for sentinel node-positive melanoma: assessment of practice patterns in the United States. Ann Surg Oncol. 2008;15(6):1566-1576.
63. Kretschmer L, Thoms K-M, Peeters S, Haenssle H, Bertsch HP, Emmert S. Postoperative morbidity of lymph node excision for cutaneous melanomasentinel lymphonodectomy versus complete regional lymph node dissection. Melanoma Res. 2008;18(1):16-21. (Pubitemid 351628051)
64. Ling A, Dawkins R, Bailey M, et al. Short-term morbidity associated with sentinel lymph node biopsy in cutaneous malignant melanoma. Australas J Dermatol. 2010;51(1):13-17.
65. Sabel MS, Griffith KA, Arora A, et al. Inguinal node dissection for melanoma in the era of sentinel lymph node biopsy. Surgery. 2007;141(6):728-735. (Pubitemid 46856567)
66. Hettiaratchy SP, Kang N, O'Toole G, Allan R, Cook MG, Powell BW. Sentinel lymph node biopsy in malignant melanoma: a series of 100 consecutive patients. Br J Plast Surg. 2000;53(7):559-562.
67. Agnese DM, Abdessalam SF, Burak WE Jr, Magro CM, Pozderac RV, Walker MJ. Cost-effectiveness of sentinel lymph node biopsy in thin melanomas. Surgery. 2003;134(4):542-548. (Pubitemid 37411959)
68. Kanzler MH. Lymphatic mapping and sentinel node biopsy: the data unclouded by speculation - in reply. Arch Dermatol. 2008;144(5):688-689. (Pubitemid 351724441)
69. Statius Muller MG, van Leeuwen PAM, de Lange-De Klerk ES, et al. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma. Cancer. 2001;91(12):2401-2408.
70. Chao C, Martin RC II, Ross MI, et al. Correlation between prognostic factors and increasing age in melanoma. Ann Surg Oncol. 2004;11(3):259-264. (Pubitemid 40486765)
71. McMasters KM, Ross MI, Reintgen DS, et al. Final results of the Sunbelt Melanoma Trial [abstract]. J Clin Oncol. 2008;26(15S)(May 20 suppl):9003.
72. Gamel JW, George SL, Edwards MJ, Seigler HF. The long-term clinical course of patients with cutaneous melanoma. Cancer. 2002;95(6):1286-1293. (Pubitemid 35013064)
73. van Akkooi ACJ, Nowecki ZI, Voit C, et al. Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes. Ann Surg. 2008;248(6):949-955.
74. Heisenberg W. Über den anschaulichen Inhalt der quantentheoretischen Kinematik und Mechanik [English translation: Wheeler JA, Zurek H. Quantum Theory and Measurement. Princeton, NJ: Princeton University Press; 1983:62-84]. Zeitschrift für Physik. 1927;43:172-198.
75. Thomas JM. Concerns relating to the conduct and statistical analysis of the Multicenter Selective Lymphadenectomy Trial (MSLT-1) in patients with melanoma. J Plast Reconstr Aesthet Surg. 2009;62(4):442-446.
76. Testori A, Rastrelli M, De Fiori E, et al. Radio-guided ultrasound lymph node localization: feasibility of a new technique for localizing and excising nonpalpable lymph nodes ultrasound suspicious for melanoma metastases. Melanoma Res. 2010;20(3):197-202.